ARNAV Biotech
Arnav Biotech is a multi-disciplinary company focused on developing efficient mRNA-based drug discovery, therapeutics, vaccines, and diagnostic applications. They offer high-quality, custom, and catalogued mRNA products, with expertise in mRNA design, optimization, and synthesis. The company collaborates on innovative projects such as developing anti-viral therapeutics and mRNA platform technologies, aiming to bring advanced solutions to healthcare and research sectors.
Industries
Nr. of Employees
small (1-50)
Products
Pre-designed capped and polyadenylated mRNA for screening
Ready-to-use, fully capped and polyadenylated mRNA constructs intended for screening delivery formulations in vitro and in vivo.
Reporter mRNA (luminescent and fluorescent)
mRNA constructs encoding luciferase and fluorescent proteins optimized for rapid expression and use in transfection efficiency assays, whole-body imaging, and biodistribution studies.
Functional enzyme-encoding mRNA
mRNA constructs encoding functional enzymes (examples include recombinase and beta-galactosidase) for use in functional screening, reporter activation, selection marker removal, and imaging assays.
Multi-epitope-tagged mRNA constructs
mRNA constructs engineered to include multiple epitope tags to permit orthogonal detection and affinity purification using standard immunoassays and tag-based methods.
Pre-designed capped and polyadenylated mRNA for screening
Ready-to-use, fully capped and polyadenylated mRNA constructs intended for screening delivery formulations in vitro and in vivo.
Reporter mRNA (luminescent and fluorescent)
mRNA constructs encoding luciferase and fluorescent proteins optimized for rapid expression and use in transfection efficiency assays, whole-body imaging, and biodistribution studies.
Functional enzyme-encoding mRNA
mRNA constructs encoding functional enzymes (examples include recombinase and beta-galactosidase) for use in functional screening, reporter activation, selection marker removal, and imaging assays.
Multi-epitope-tagged mRNA constructs
mRNA constructs engineered to include multiple epitope tags to permit orthogonal detection and affinity purification using standard immunoassays and tag-based methods.
Services
Contract synthesis of user-designed or company-designed mRNA with options for base modifications, cap structures, poly(A) tails, phosphatase treatment, and selectable resuspension buffers.
Off-the-shelf research mRNAs including reporter constructs (luminescent and fluorescent), functional enzymes (recombinase, beta-galactosidase), and multi-tagged constructs for detection and purification.
Development of synthesis and purification processes that combine chromatographic purification and in-process analytics to improve yield and purity for mRNA therapeutics.
Support services aimed at progressing candidates to pre-IND and IND-enabling studies, including biological testing and process readiness for regulatory submission activities.
Contract synthesis of user-designed or company-designed mRNA with options for base modifications, cap structures, poly(A) tails, phosphatase treatment, and selectable resuspension buffers.
Off-the-shelf research mRNAs including reporter constructs (luminescent and fluorescent), functional enzymes (recombinase, beta-galactosidase), and multi-tagged constructs for detection and purification.
Development of synthesis and purification processes that combine chromatographic purification and in-process analytics to improve yield and purity for mRNA therapeutics.
Support services aimed at progressing candidates to pre-IND and IND-enabling studies, including biological testing and process readiness for regulatory submission activities.
Expertise Areas
- mRNA design and optimization
- Custom mRNA manufacturing
- mRNA purification and analytics
- Process development and scale-up for mRNA
Key Technologies
- mRNA synthesis
- Modified nucleoside incorporation
- 5' capping methods
- Poly(A) tail engineering
News & Updates
ARNAV Biotech has secured an exclusive license for a novel anti-RSV therapeutics, ARNV-F2, a fusion inhibitor that blocks RSV infection, aiming to move quickly to pre-IND and IND studies.
ARNAV Biotech has secured an exclusive license for a novel anti-RSV therapeutics, ARNV-F2, a fusion inhibitor that blocks RSV infection, aiming to move quickly to pre-IND and IND studies.